-+ 0.00%
-+ 0.00%
-+ 0.00%
Gilead Expects HIV Revenue to Grow About 12% in 2026
Share
Listen to the news
Gilead Expects HIV Revenue to Grow About 12% in 2026
  • Gilead expects fiscal 2026 HIV revenue growth of about 12%, with Yeztugo revenue forecast at approximately $1 billion.
  • Third-quarter HIV sales rose 18% to $6.2 billion, supporting the outlook.
  • Cell therapy revenue is expected to decline by a mid-teens percentage in 2026 amid competitive headwinds; Veklury revenue should total approximately $300 million.
  • Medicare pricing changes are projected to reduce Biktarvy revenue by approximately $1.5 billion in 2028 versus 2027, including spillover into other payer channels.
  • Biktarvy’s Medicare price will be $2,600 per 30-day supply starting January 1, 2028, approximately 38% below list price.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on November 14, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending